AKT signaling in ERBB2-amplified breast cancer

The PI3K/AKT pathway is the focus of several targeted therapeutic agents for a variety of malignancies. In ERBB2-amplified breast cancer, the hyperactivation of this signaling cascade is associated with resistance to ERBB2-targeted therapy. This can occur through gain-of-function alterations or comp...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Pharmacol Ther
Glavni autori: Carmona, F Javier, Montemurro, Filippo, Kannan, Srinivasaraghavan, Rossi, Valentina, Verma, Chandra, Baselga, José, Scaltriti, Maurizio
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4747800/
https://ncbi.nlm.nih.gov/pubmed/26645663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2015.11.013
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items